linjc16/ctgov huggingface dataset:
Clear Aligner Versus Removable Inclined Plane in Treatment of Anterior Crossbite

Study Overview
=================
Brief Summary
-----------------
the study is carried in faculty of dentistry Mansoura university to compare the efficiency and health quality life improvement between clear aligner and inclined plane in treatment of anterior crossbite

Detailed Description
-----------------
the study *include 24 patient each group include 12 patient where randomly allocated and intra-oral scanning is done for them followed by software designing ,printing using PETG sheets of 0.75 in aligner group while in inclined plane the appliance is formed in conventional way.

Official Title
-----------------
Clear Aligner Versus Removable Inclined Plane in Treatment of Anterior Crossbite

Conditions
-----------------
Anterior Crossbite

Intervention / Treatment
-----------------
* Other: inclined plane
* Other: clear aligner


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:1. Patients age (7-12) years. 2. anterior crossbite 3. More than one tooth in a crossbite. 4. Favorable oral hygiene 5. No oral habits 6. ANB within the normal range i.e. (The crossbite will be diagnosed as functional or dental) - Exclusion Criteria: Systemic conditions that may interfere with the treatment. Bad habits that might jeopardize the appliance. Transverse discrepancy. Previous orthodontic treatment

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: inclined plane<br>group treated with inclined plane | Other: inclined plane<br>* 2 parallel groups one treated with clear aligner and other treated using inclined plane<br>|
| Experimental: clear aligner<br>group treated with clear aligner | Other: clear aligner<br>* 2 parallel groups one treated with clear aligner and other treated using inclined plane<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| (OHRQoL (Oral Health-related Quality of Life) | CPQ8-10 scores at two different points in time. | 4 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cephalometric analysis of data | compare cephalometric variables between two groups | 4 month | 
| 3D model measurements | compare 3D model measurements variable between 2 group | 4 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
clear aligner , anterior crossbite , inclined plane
Study of Patient Preferences in Relation to the Fitting of a Personalized and Connected Joint Prosthesis.

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about patients' preference toward the use of customized and connected prosthesis. The main questions it aims to answer are: What is the acceptability of new customization and connectivity technologies by patients? Are they all at the same level of acceptability? Participants will have to answer to a questionnaire of choice.

Official Title
-----------------
Study of Patient Preferences in Relation to the Fitting of a Personalized and Connected Joint Prosthesis.

Conditions
-----------------
Prosthesis User, Orthopedic Disorder

Intervention / Treatment
-----------------
* Other: Answering preference


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: More than 18 Non opposition expressed Should have a hip, knee or shoulder joint replacement Exclusion Criteria: Opposition expressed Having already a hip, knee or shoulder joint prosthesis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Preference study<br>Patients answering the questionnaire with choice sets | Other: Answering preference<br>* Patients will answer a questionnaire with two possible choices describing several scenario of used of customized and connected prosthesis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gathering preferences for a customized and connected prosthesis by Discrete choice analysis, and with a questionnaire called Discrete Choice Experiment, based on RUT (Random Utility Theory). | Patient will choose one scenario between the two proposed in the eight choice sets. Then, based on RUT (Random Utility Theory), a conditionnal logit and Mixed logit will be used to calculate the beta coefficiants of the attributes that allow to measure the prefered choice relating to the technology tested | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measuring the ease of use of new technologies through ATI (Affinity for Technology Interaction) scale | Several question about the use of technologies by patients in their daily life are asked. Scale ranges from 1-2 (very low affinity) to 5-6 (very high affinity). | 6 month |
Pregnancy Outcomes of Patients Having NC-FET Regarding the Progesterone Levels

Study Overview
=================
Brief Summary
-----------------
We recently identify in our previous study 'NCT052115832' the progesterone levels for the embryo transfer in natural thaw cycles. Since it is shown that progesterone levels work better than LH levels in order to detect the time to transfer, we aimed to show the pregnancy outcomes of the natural thaw cycles which had the transfer date regarding the progesterone levels.

Official Title
-----------------
Evaluation of the Pregnancy Outcomes and Time to Embryo Transfer Regarding the Progesterone Levels of Natural Cycle-FETs

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with regular menstrual cycle patients aged btw 20-40 patients with pregnancy with NC-FET by using the progesterone for the detection of ovulation Exclusion Criteria: Spontenous pregnancies Multiple pregnancies

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cummulative Live Birth Rate | Live birth rates of Patient with NC-FET followed up with progesterone levels | 10 months | 
| Biochemical pregnancy results | Biochemical pregnancy results of patients with NC-FET followed up with progesterone levels | 2 months | 
| Pregnancy complications | Obstetric Complications of Patient with NC-FET followed up with progesterone levels | 10 months |
Low Dose Atropine for Symptomatic Vitreous Floaters

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Official Title
-----------------
Low Dose Atropine For Symptomatic Vitreous Floaters

Conditions
-----------------
Vitreous Floaters

Intervention / Treatment
-----------------
* Drug: 0.01% atropine ophthalmic drop


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants. Exclusion Criteria: Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Atropine 0.01%<br>Patients will apply 1 drop daily of atropine 0.01% | Drug: 0.01% atropine ophthalmic drop<br>* 0.01% atropine ophthalmic drop will be applied daily to the affected eye<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom improvement assessed by questionnaire | NEI VFQ-25 = National Eye Institute Visual Function Questionnaire | Up to 2 months |
Systemic Management in Extremely Preterm and Extremely Low Birth Weight Infants

Study Overview
=================
Brief Summary
-----------------
to estimate incidences of major complications, such as bronchopulmonary dysplasia, death, and delivery room resuscitation among extremely preterm and extremely low birth weight infants in Northern China

Detailed Description
-----------------
to estimate incidences and risk factors of bronchopulmonary dysplasia, death, and delivery room resuscitation among extremely preterm and extremely low birth weight infants in Northern China

Official Title
-----------------
Systemic Management in Extremely Preterm and Extremely Low Birth Weight Infants

Conditions
-----------------
Bronchopulmonary Dysplasia, Death

Intervention / Treatment
-----------------
* Other: no interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: born between January 1, 2015, and December 31, 2018; a birth weight <1000grams or a gestational age <28 weeks; admitted within 72 hours after birth. Exclusion Criteria: No medical history in the electronic record

Ages Eligible for Study
-----------------
Maximum Age: 72 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| <28 weeks and <1000 grams<br>By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study. | Other: no interventions<br>* no interventions because of an observational study<br>|
| <28 weeks and ≥1000 grams<br>By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study. | Other: no interventions<br>* no interventions because of an observational study<br>|
| ≥28 weeks and <1000 grams<br>By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study. | Other: no interventions<br>* no interventions because of an observational study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidences | to investigate incidences of bronchopulmonary dysplasia | at 36 weeks' corrected age (CA) or at discharge | 
| risk factors | to investigate risk factors of bronchopulmonary dysplasia | at 36 weeks' corrected age (CA) or at discharge | 
| incidences of delivery room resuscitation | to investigate incidences of delivery room resuscitation | on admission | 
| risk factors of delivery room resuscitation | to investigate risk factors of delivery room resuscitation | on admission |
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Study Overview
=================
Brief Summary
-----------------
Comparison nafamostat and low molecular weight heparin among dialysis patients

Official Title
-----------------
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study

Conditions
-----------------
Dialysis; Complications, Bleeding

Intervention / Treatment
-----------------
* Drug: Nafamostat Mesylate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month Exclusion Criteria: cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: nafamostat<br>Patients received dialysis through nafamostat | Drug: Nafamostat Mesylate<br>* Comparison effect of nafamostat and cnoxan<br>* Other names: cnoxan;|
| No Intervention: Cnoxane<br>Patients received dialysis through cnoxan | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with severe bleeding | Brain hemorrhage (on brain CT), gastrointestinal bleeding (on EGD) | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with dialysis circuit clot | Dialysis circuit clotting due to not enough anticoagulation | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dialysis, bleeding, nafamostat, heaprin
Menstrual Cycle Study

Study Overview
=================
Brief Summary
-----------------
A data collection study to develop algorithms to estimate menstrual cycle phases.

Official Title
-----------------
Study for the Development of Biometrics-informed Menstrual Cycle Algorithms

Conditions
-----------------
Menstruation, Ovulation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Adults who are between 18 - 42 years old at enrollment and menstruate Capable of giving informed consent in Spanish or English Menstrual cycle lengths between 21- 45 days Have tracked menstruation for at least 3 menstrual cycles out of the prior 6 months Willing to wear a wrist-worn wearable device continuously for 6 months Willing to use an ovulation predictor kit for 6 months Willing to report vaccine history Owns a smartphone compatible with the study and has access to wi-fi Exclusion: A citizen of the European Union or United Kingdom Trying to conceive during the six-month study period Have used specific forms of birth control in the 3 months prior to the study or planning on using specific birth control methods during the study duration Participant has undergone hormonal treatment in the past 3 months or planning to do so during the study Known history of health-related issues that affect their menstrual cycle, history of pelvic radiation, vasomotor symptoms, endometriosis, fibroids, polyps, ovarian cysts or known history of health-related issues that affect the physiology Currently (or within the past 3 months) engaged in health impacting behaviors Have been breastfeeding or pregnant in the past 6 months prior to the study On medications or taking substances that could affect their menstrual cycle or physiology Travel frequently such as crossing more than two time zones at least once every 2 weeks Have a known sleeping disorder or consistently work night shifts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Participants<br>Up to 150 participants will be enrolled at one or more clinical research sites in the United States. Participants will be healthy, menstruating individuals between 18 to 42 years of age who meet all eligibility criteria. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ovulation Day Estimation | The algorithm's estimated ovulation day compared to the reference urinary ovulation predictor kits (OPK). | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Menstruation Day Estimation | The algorithm's estimated menstruation date(s) compared to participants' self-reported menstruation date(s). | 6 months |
Pilot Study of Percutaneous Correction of Hallux Valgus

Study Overview
=================
Brief Summary
-----------------
This is a pilot study with a randomized controlled design.

Official Title
-----------------
Pilot Study of Percutaneous Correction of Hallux Valgus: Clinical-functional Evaluation of Outcome Randomized Study

Conditions
-----------------
Hallux Valgus

Intervention / Treatment
-----------------
* Procedure: SERI osteotomy
* Procedure: percutaneous osteotomy according to Chevron


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of both sexes with adult hallux valgus with indication for corrective surgical treatment HVA (hallux valgus angle): 20°-40° IMA (intermetatarsal angle): 10°-20° Exclusion Criteria: Patients with instability of the first metatarsophalangeal joint Patients with severe morphostructural alterations or other pathologies in the foot and lower limb patients requiring additional surgical procedures patients with severe vascular and neurological systemic pathologies systemic pathologies that may impair bone consolidation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: standard treatment<br>SERI osteotomy | Procedure: SERI osteotomy<br>* Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire<br>|
| Experimental: experimental treatment<br>percutaneous osteotomy according to Chevron | Procedure: percutaneous osteotomy according to Chevron<br>* Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analog Score | pain visual analog assessment | baseline | 
| Visual Analog Score | pain visual analog assessment | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| American Orhtopaedic Foot and Ankle Society forefoot score | range of motion evaluation | baseline and aftef 1 year |
Wet Cupping Therapy in Ankylosing Spondylitis

Study Overview
=================
Brief Summary
-----------------
This study evaluates the efficacy of wet cupping therapy in patients with ankylosing spondylitis.Wet cupping therapy will be applied to half of the patients plus routine pharmaceutical treatment while the other half will receive only pharmaceutics

Detailed Description
-----------------
In addition to the medical treatment, WCT will be applied once a month, 3 times (Day 0, 30, 60) to the intervention group whereas the control group will not receive any intervention. The BASFI, BASDAI, VAS and Schober test will be applied to both groups at 0 and 3 months.

Official Title
-----------------
Wet Cupping Therapy in Ankylosing Spondylitis: a Multicenter Randomised Controlled Trial

Conditions
-----------------
Ankylosing Spondylitis

Intervention / Treatment
-----------------
* Procedure: wet cupping therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of ankylosing spondylitis 18-65 years of age Consent to participate Exclusion Criteria: Any ongoing medical treatment other than NSAIDs Pregnancy At least one contraindication to WCT that was detected in subject's history or in the routine blood examinations prior to enrollment (Hgb <9.5; INR> 1.2; history of hemophobia, bleeding disorder, malignant disorder).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Wet cupping arm<br>This arm is the interventiom group and will receive three consecutive sessions of wet cupping therapy once a month. | Procedure: wet cupping therapy<br>* wet cupping therapy will be applied to participants in this arm for three sessions once a month<br>|
| No Intervention: Control arm<br>This arm is the control group and will not receive any intervention other than the routine medications | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BASFI | Change in the scores of The Bath Ankylosing Spondylitis Functional Index | At 0 and 3 months | 
| BASDAI | Change in the scores of The Bath Ankylosing Spondylitis Disease Activity Index | At 0 and 3 months | 
| VAS | Change in the scores of Visual Analogue Scale | At 0 and 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Schober | Change in the scores of Modified Schober Test | At 0 and 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Basfi, Ankylosing Spondylitis, Wet cupping therapy, Basdai, Vas